The precarious question for the pharmaceutical companies is how to advance their business model in order to flourish in a world of shifting profit pools by converging on outcomes rather than by solely generating more inputs – more products, more procedures and ultimately more cost to the payers.
Stakeholders are demanding more evidence of comparative or cost effectiveness for new drugs. Understanding the prerequisites and wants of payers and key influencers are crucial for a successful market access strategy. For effective value proposition, configuration is required with all stakeholders, including payers, making it necessary to assess value messages and the overall proposition throughout development.
At MarksMan, we offer payer and key influencer mapping to guide clients in confronting specific pricing and reimbursement issues; assisting in drafting of the “Local Value Dossiers”. Our workforce has an extensive experience both in the pharmaceutical industry and dealing with HTA bodies and other agencies (ESI, CGHS, Railways, Defense, State and Central Govt.) to assist “Payer Partnership Plans” (PPP) with the aim to capitalize on reimbursement.
We bring experience to ensure that the key stakeholders expectations and requests are copiously met, and ensuring the listing in the said formulary.